[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI3395821T1 - Protitumorske spojine - Google Patents

Protitumorske spojine

Info

Publication number
SI3395821T1
SI3395821T1 SI201830003T SI201830003T SI3395821T1 SI 3395821 T1 SI3395821 T1 SI 3395821T1 SI 201830003 T SI201830003 T SI 201830003T SI 201830003 T SI201830003 T SI 201830003T SI 3395821 T1 SI3395821 T1 SI 3395821T1
Authority
SI
Slovenia
Prior art keywords
antitumoral compounds
antitumoral
compounds
Prior art date
Application number
SI201830003T
Other languages
English (en)
Inventor
Marchante Maria Del Carmen Cuevas
Solloso Andres Francesch
Barrasa Valentin Martinez
Original Assignee
Pharma Mar, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar, S.A. filed Critical Pharma Mar, S.A.
Publication of SI3395821T1 publication Critical patent/SI3395821T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
SI201830003T 2017-04-27 2018-04-27 Protitumorske spojine SI3395821T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382228 2017-04-27
EP17382497 2017-07-26
EP18382288.1A EP3395821B1 (en) 2017-04-27 2018-04-27 Antitumoral compounds

Publications (1)

Publication Number Publication Date
SI3395821T1 true SI3395821T1 (sl) 2019-09-30

Family

ID=62063080

Family Applications (5)

Application Number Title Priority Date Filing Date
SI201830902T SI3615544T1 (sl) 2017-04-27 2018-04-27 Protitumorske spojine
SI201830002T SI3395820T1 (sl) 2017-04-27 2018-04-27 Protitumorske spojine
SI201830966T SI4101855T1 (sl) 2017-04-27 2018-04-27 Protitumorske spojine
SI201830003T SI3395821T1 (sl) 2017-04-27 2018-04-27 Protitumorske spojine
SI201830901T SI4047002T1 (sl) 2017-04-27 2018-04-27 Protitumorske spojine

Family Applications Before (3)

Application Number Title Priority Date Filing Date
SI201830902T SI3615544T1 (sl) 2017-04-27 2018-04-27 Protitumorske spojine
SI201830002T SI3395820T1 (sl) 2017-04-27 2018-04-27 Protitumorske spojine
SI201830966T SI4101855T1 (sl) 2017-04-27 2018-04-27 Protitumorske spojine

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201830901T SI4047002T1 (sl) 2017-04-27 2018-04-27 Protitumorske spojine

Country Status (37)

Country Link
US (5) US10538535B2 (sl)
EP (5) EP3395821B1 (sl)
JP (5) JP6501946B2 (sl)
KR (3) KR102492283B1 (sl)
CN (4) CN114751920B (sl)
AU (4) AU2018260314C1 (sl)
BR (1) BR112019022282A2 (sl)
CA (1) CA3061518A1 (sl)
CL (1) CL2019003057A1 (sl)
CO (1) CO2019011967A2 (sl)
CY (3) CY1121885T1 (sl)
DK (5) DK3615544T3 (sl)
EC (1) ECSP19083967A (sl)
ES (5) ES2740073T3 (sl)
FI (3) FI4047002T3 (sl)
HK (2) HK1255941B (sl)
HR (5) HRP20230455T1 (sl)
HU (5) HUE062032T2 (sl)
IL (3) IL289963B2 (sl)
JO (1) JOP20190254A1 (sl)
LT (5) LT4047002T (sl)
MA (2) MA44021B1 (sl)
MD (5) MD3615544T2 (sl)
ME (2) ME03467B (sl)
MX (3) MX2021016054A (sl)
MY (1) MY198004A (sl)
PH (1) PH12019550224A1 (sl)
PL (5) PL4101855T3 (sl)
PT (2) PT3395820T (sl)
RS (5) RS64686B1 (sl)
SG (2) SG10201913300YA (sl)
SI (5) SI3615544T1 (sl)
TN (2) TN2019000211A1 (sl)
TW (3) TWI807411B (sl)
UY (1) UY37706A (sl)
WO (1) WO2018197663A1 (sl)
ZA (1) ZA201907119B (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
EP4061372A1 (en) * 2019-11-21 2022-09-28 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
CA3175426A1 (en) 2020-04-21 2021-10-28 Alfonso Latorre Lozano Drug antibody conjugates
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
MX2023013715A (es) 2021-05-19 2024-03-26 Pharma Mar Sa Regímenes de dosis de ecubectedina.
WO2024186263A1 (en) * 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3205220A (en) 1961-10-26 1965-09-07 Lilly Co Eli Leurosidine and leurocristine and their production
US4762949A (en) 1979-06-20 1988-08-09 University Of Illinois Foundation Acyl and carbamimidoyl alkanediamines
GB2058047B (en) 1979-07-11 1983-09-21 Asahi Chemical Ind Amides and amidines
FR2461995A1 (fr) 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4782135A (en) 1980-09-12 1988-11-01 Board Of Trustees, University Of Illinois Composition of matter and process
US5137870A (en) 1980-09-12 1992-08-11 The Board Of Trustees Of The University Of Illinois Didemnins and nordidemnins
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
EP0048149B1 (en) 1980-09-12 1983-11-30 University of Illinois Foundation Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4548814A (en) 1980-12-18 1985-10-22 The Board Of Trustees Of The University Of Illinois Composition of matter and process
JPS5922518A (ja) 1982-07-29 1984-02-04 余合住金産業株式会社 洋服タンス
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
EP0207124B1 (en) 1984-12-28 1991-10-09 Conpharm Ab Use of podophyllotoxin and derivatives thereof
US4644072A (en) 1985-04-12 1987-02-17 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
EP0220453B1 (de) 1985-09-20 1992-04-15 Cernitin S.A. Verwendung von Pflanzenpollenextrakten zur Herstellung von das Wachstum von Tumorzellen hemmenden pharmazeutischen Präparaten und Verfahren zu ihrer Herstellung
US4731377A (en) 1986-01-31 1988-03-15 Harbor Branch Oceanographic Institute, Inc. Antitumor cyclic peroxides
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
EP0309477B1 (en) 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4737510A (en) 1986-09-30 1988-04-12 The Board Of Trustees Of The University Of Illinois Bioactive metabolites from the caribbean sponge agelas coniferin
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4847246A (en) 1987-09-11 1989-07-11 Wilson George R Antiviral compositions derived from fireflies and their methods of use
FR2623504B1 (fr) 1987-11-25 1990-03-09 Adir Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
ATE83480T1 (de) 1988-09-05 1993-01-15 Sankyo Co Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
WO1990005731A1 (en) 1988-11-24 1990-05-31 University Of Queensland Cytotoxic macromolecules
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
CA2007507C (en) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5053559A (en) 1989-12-29 1991-10-01 Oxaco S.A. Cleavage of 1,2,4-trioxanes
KR910014122A (ko) 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
GB9212000D0 (en) 1992-06-05 1992-07-15 Univ Madrid Complutense New synthetic antitumoral compound
WO1994004541A2 (en) 1992-08-12 1994-03-03 The Upjohn Company Protein kinase inhibitors and related compounds combined with taxol
US5756734A (en) 1992-09-11 1998-05-26 Pharmamar, S.A. Crambescidins: new antiviral and cytotoxic compounds from the sponge crambe crambe
ES2059259B1 (es) 1992-09-22 1995-10-01 Pharma Mar S A Pharmar Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral.
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302044D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Cytotoxic compounds i
US5569757A (en) 1993-03-30 1996-10-29 Rinehart; Kenneth L. 9-deazaadenosine and its 5'-α-D-glycopyranoside isolated from the cyanobacterium anabaena affinis strain VS-1
GB9308111D0 (en) 1993-04-20 1993-06-02 Pharma Gen S A Active compound from a stonge
US5556777A (en) 1993-09-09 1996-09-17 Pharmamar, S.A. Immunosuppressive pharmaceutical compositions new biological activity from a marine agrobacterium sp.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5514708A (en) 1994-02-18 1996-05-07 Pharmamar, S.A. Cytotoxic metabolites from Myriapora truncata
US5681813A (en) 1994-04-06 1997-10-28 Pharma Mar, S.A. Thiodepsipeptide isolated from a marine actinomycete
ES2100124B1 (es) 1994-08-01 1998-04-01 Pharma Mar Sa Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral.
US5514705A (en) 1994-09-07 1996-05-07 Pharmamar, S.A. Epidioxymanadic acids A and B
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9422946D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Antineoplastic cyclolignan derivatives
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
GB9504662D0 (en) 1995-03-08 1995-04-26 Pharma Mar Sa Antitumour isocoumarins
US20010039041A1 (en) 1995-06-07 2001-11-08 Pharma Mar, S.A. Immunosuppressive sesbanimide compositions and methods of treatment using same
US5661175A (en) 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US5852033A (en) 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US5681847A (en) 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
GB9608010D0 (en) 1996-04-18 1996-06-19 Pharma Mar Sa Trunkamide A
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
CA2269881A1 (en) 1996-10-24 1998-04-30 The Board Of Trustees Of The University Of Illinois Semi-synthetic studies toward didemnin analogues
DE69723728T2 (de) 1996-10-24 2004-06-03 The Board Of Trustees For The University Of Illinois, Urbana Totalsynthese des amino hip analogen von didemnin a
GB9622427D0 (en) 1996-10-28 1997-01-08 Pharma Mar Sa Antimalarial drugs
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
US6028077A (en) 1997-04-15 2000-02-22 Rinehart; Kenneth L. Crambescidin compounds
US6107520A (en) 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
USRE38793E1 (en) 1997-04-15 2005-09-06 Rinehart Kenneth L Spisulosine compounds
AUPO656597A0 (en) 1997-05-02 1997-05-29 Australian National University, The Preparation of therapeutic compounds
EP0981352B8 (en) 1997-05-07 2009-06-17 Pharma Mar, S.A. Use of aplidine for the treatment of cardiovascular diseases
GB9723206D0 (en) 1997-11-03 1998-01-07 Inst Biomar Sa New cytotoxic pyridoacridine alkaloids
US6420357B1 (en) 1997-12-23 2002-07-16 Instituto Biomar, S.A. Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge
GB9727301D0 (en) 1997-12-23 1998-02-25 Inst Biomar Sa Asmarine A and B: New cytotoxic alkaloids
GB9801741D0 (en) 1998-01-27 1998-03-25 Inst Biomar Sa New cytotoxic tris (oxazole)-containing macrolides
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
EP1067933B1 (en) 1998-04-06 2007-08-15 The Board Of Trustees Of The University Of Illinois Semi-synthetic ecteinascidins
US6656948B2 (en) 1998-04-29 2003-12-02 Universidad Complutense De Madrid Cytotoxic compounds: derivatives of the pyrido[2,3,4-kl]acridine ring system
DE69927014T2 (de) 1998-05-05 2006-06-14 Pharma Mar Sa Kultivierung von sessilen meerestieren
WO1999058125A1 (en) 1998-05-11 1999-11-18 Pharma Mar, S.A. Metabolites of ecteinascidin 743
GB9810998D0 (en) 1998-05-21 1998-07-22 Univ Madrid Complutense Antitumour 1,5-diazaanthraquinones
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB9915069D0 (en) 1999-06-28 1999-08-25 Inst Biomar Sa New indolocarbazole alkaloids from a marine actinomycete
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
ES2288486T3 (es) 1999-11-15 2008-01-16 Pharma Mar, S.A. Tratamiento de canceres con aplidina.
JP2003520801A (ja) 2000-01-19 2003-07-08 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US6864283B2 (en) 2000-02-16 2005-03-08 Pharma Mar, S.A. Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
US20030187075A1 (en) 2000-03-20 2003-10-02 Junichi Tanaka Keith Sponge antitumor compounds
MXPA02009943A (es) 2000-04-07 2003-04-25 Univ Pennsylvania Analogos de tamandarin y didemnin y metodos para hacerlos y usarlos.
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
MXPA02010088A (es) 2000-04-12 2004-08-19 Pharma Mar Sa Derivados de ecteinascidina antitumorales.
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
GB0010799D0 (en) 2000-05-04 2000-06-28 Inst Biomar Sa Stolonoxides
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
GB0011927D0 (en) 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
US7138547B2 (en) 2000-06-06 2006-11-21 Pharma Mar, S.A. Antitumoral compounds
GB0016020D0 (en) 2000-06-29 2000-08-23 Inst Biomar Sa New polyciclic xanthones and their use
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
US7320981B2 (en) 2000-07-11 2008-01-22 Pharma Mar, S.A. Variolin derivatives as anti-cancer agents
EP2275175B1 (en) 2000-07-13 2016-08-24 ReCor Medical, Inc. Thermal treatment apparatus with ultrasonic energy application
GB0019117D0 (en) 2000-08-03 2000-09-27 Univ Barcelona Derivatives of variolin B
HUP0302293A3 (en) 2000-10-12 2006-04-28 Pharma Mar Sa Treatment of cancers by aplidine in conjunction with a myoprotector
IL155273A0 (en) 2000-10-12 2003-11-23 Pharma Mar Sa Pharmaceutical compositions comprising an aplidine compound
MXPA03003704A (es) 2000-10-31 2004-05-04 Pharma Mar Sa Formulacion de kahalalide f.
EP1365808B1 (en) 2000-11-06 2011-01-19 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
EP1353659A1 (de) 2001-01-24 2003-10-22 Mestex AG Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen
CZ20032022A3 (cs) 2001-01-25 2004-04-14 Bristol-Myers Squibb Company Parenterální prostředek obsahující epothilonová analoga
WO2002064843A1 (en) 2001-02-09 2002-08-22 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
GB0105745D0 (en) 2001-03-08 2001-04-25 Pharma Gen S A Immobilisation of ligands
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
GB0116966D0 (en) 2001-07-11 2001-09-05 Pharma Mar Sa Anittumoral compounds
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
PL368458A1 (en) 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
EP1435991B1 (en) 2001-10-19 2008-10-15 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
EP1435990A1 (en) 2001-10-19 2004-07-14 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0217638D0 (en) 2002-07-30 2002-09-11 Pharma Mar Sa Total synthesis of myriaporones
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0218816D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa Antitumoral analogs of lamellarins
US20040033940A1 (en) 2002-08-16 2004-02-19 Pharma Mar, S.A. Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP
WO2004035613A2 (en) 2002-10-18 2004-04-29 Pharma Mar, S.A.U. 4-methylhexanoic kahalaide f compound
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0303940D0 (en) 2003-02-20 2003-03-26 Pharma Mar Sau Solid phase synthesis of antitumoral compounds
CA2516455C (en) 2003-02-20 2012-05-01 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
AU2004220451B2 (en) 2003-03-12 2010-01-21 Pharma Mar, S.A. Improved antitumoral treatments
CA2519789C (en) 2003-03-12 2012-07-03 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
EP1613338A4 (en) 2003-03-21 2009-06-24 Madeleine M Joullie TAMANDARIN ANALOGUES, FRAGMENTS THEREOF AND METHODS OF MAKING AND USING THE SAME
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
WO2005005601A2 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
GB0314726D0 (en) 2003-06-24 2003-07-30 Inst Biomar Sa New cytotoxic depsipeptides
EP1651633A1 (en) 2003-07-25 2006-05-03 Novartis AG Substituted lactams and their use as anti-cancer agents
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
DE602004018811D1 (de) 2003-10-09 2009-02-12 Abbott Lab Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
EP1689404B9 (en) 2003-11-13 2009-04-22 Pharma Mar, S.A.U. Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
CN1897949A (zh) 2003-11-14 2007-01-17 马尔药品公司 包含使用et－743和紫杉醇来治疗癌症的联合疗法
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
DE102004011809A1 (de) 2004-03-11 2005-09-29 Robert Bosch Gmbh Magnetsensoranordnung
GB0408958D0 (en) 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
WO2005118584A2 (en) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
EP1768671A2 (en) 2004-07-09 2007-04-04 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
EP1812114A2 (en) 2004-09-29 2007-08-01 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti-inflammatory agents
BRPI0518250A2 (pt) 2004-10-26 2008-11-11 Pharma Mar Sa tratamentos anticÂncer
EP1658848B1 (en) 2004-10-29 2007-08-01 Pharma Mar S.A., Sociedad Unipersonal Formulations comprising ecteinascidin and a disaccharide
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
WO2006066183A2 (en) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
EP1879870A1 (en) 2005-05-03 2008-01-23 Pharma Mar, S.A. Antitumoral tetrahydro-pyrimidines
GB0515673D0 (en) 2005-08-01 2005-09-07 Pharma Mar Sa Antitumoral compounds
RU2008107974A (ru) 2005-08-02 2009-09-10 Фарма Мар, С.А. (Es) Гены, участвующие в биосинтезе тиокоралина и его гетерологичном продуцировании
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0523098D0 (en) 2005-11-14 2005-12-21 Pharma Mar Sa Antitumoral compounds
CA2630900A1 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
ES2276629B1 (es) 2005-12-15 2009-04-01 Pharma Mar, S.A. Compuestos antitumorales.
ES2288107B1 (es) 2006-01-27 2008-11-01 Fundacion Imabis Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanita Derivados aciclicos saturados e insaturados de cadena larga de sulfamidas como activadores especificos de receptores ppar-alfa.
PT2029155E (pt) 2006-02-28 2016-06-17 Pharma Mar Sa Tratamento melhorado de mieloma múltiplo
EP2023931A2 (en) 2006-05-12 2009-02-18 Pharma Mar S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
PT2032551E (pt) 2006-06-16 2011-12-06 Pharma Mar Sa Compostos de dihidropiran-2-ona antitumorais
AU2008313627A1 (en) 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
CA2703720A1 (en) 2007-10-19 2009-04-23 Albert Einstein College Of Medicine Of Yeshiva University Improved antitumoral treatments
AU2008313634A1 (en) 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for ET-743 treatment
JP5577256B2 (ja) 2007-12-14 2014-08-20 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍化合物
MY155342A (en) 2007-12-20 2015-10-15 Pharma Mar Sa Antitumoral compounds
CA2713459A1 (en) 2008-01-30 2009-08-06 Pharma Mar, S.A. Improved antitumoral treatments
MX2010009697A (es) 2008-03-07 2010-09-30 Pharm Mar S A Tratamientos anticancerigenos mejorados.
RU2010140890A (ru) 2008-03-07 2012-04-20 Фарма Мар, С.А. (Es) Улучшенные способы противоопухолевого лечения
NZ589269A (en) 2008-05-16 2013-03-28 Pharma Mar Sa Combination therapy with an antitumor alkaloid
NZ589270A (en) 2008-05-16 2011-12-22 Pharma Mar Sa Multiple myeloma treatments
JP2011520979A (ja) 2008-05-23 2011-07-21 ワイス・エルエルシー ＰＩ３キナーゼおよびｍＴＯＲ阻害剤としてのトリアジン化合物
MX2011000144A (es) 2008-07-03 2011-02-24 Pharma Mar Sa Compuestos antitumorales.
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
AU2009272661A1 (en) 2008-07-17 2010-01-21 Pharma Mar, S.A. Anticancer compounds
WO2010070078A1 (en) 2008-12-19 2010-06-24 Pharma Mar, S.A. Anticancer compounds
WO2010149688A2 (en) 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds
DK2563803T3 (en) 2010-04-27 2016-05-30 Pharma Mar Sa Anticancer-steroidal lactones, which is unsaturated at position 7 (8)
JP6037337B2 (ja) * 2010-05-25 2016-12-07 ファルマ、マール、ソシエダード、アノニマＰｈａｒｍａ Ｍｒｓ，Ｓ．Ａ． エクチナサイジン化合物の製造のための合成方法
LT2786753T (lt) 2010-11-12 2019-04-10 Pharma Mar S.A. Derinių terapija su antinavikiniu antibiotiku
DE102012211024B4 (de) 2012-06-27 2024-10-24 Robert Bosch Gmbh Verfahren zum Betreiben eines Fahrzeuges
JP5922518B2 (ja) 2012-07-20 2016-05-24 浜松ホトニクス株式会社 シンチレータパネル及び放射線検出器
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
MX2019000536A (es) 2016-07-14 2019-04-01 Pfizer Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
JOP20190254A1 (ar) * 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
TW201906850A (zh) 2019-02-16
JP2022130682A (ja) 2022-09-06
SI3615544T1 (sl) 2023-07-31
US20220242883A1 (en) 2022-08-04
AU2022200249C1 (en) 2022-06-23
CN114751920A (zh) 2022-07-15
US20210070775A1 (en) 2021-03-11
PL4047002T3 (pl) 2023-07-24
TW202202509A (zh) 2022-01-16
MX2021016054A (es) 2022-06-01
KR20210126791A (ko) 2021-10-20
CY1126061T1 (el) 2023-11-15
KR20200012846A (ko) 2020-02-05
CY1121884T1 (el) 2020-10-14
JP2023052597A (ja) 2023-04-11
DK4047002T3 (da) 2023-05-01
IL289963B1 (en) 2023-06-01
AU2022201657A1 (en) 2022-03-31
US10538535B2 (en) 2020-01-21
EP4101855B9 (en) 2024-01-03
RS64200B1 (sr) 2023-06-30
ES2944579T3 (es) 2023-06-22
UY37706A (es) 2018-11-30
HRP20230433T1 (hr) 2023-07-07
DK3615544T3 (da) 2023-05-30
MY198004A (en) 2023-07-25
EP3395821A1 (en) 2018-10-31
EP3395821B1 (en) 2019-05-15
SI3395820T1 (sl) 2019-09-30
SG10201913300YA (en) 2020-03-30
TWI742273B (zh) 2021-10-11
MD3395820T2 (ro) 2019-10-31
TW202344509A (zh) 2023-11-16
ES2960063T3 (es) 2024-02-29
LT3395820T (lt) 2019-08-12
DK4101855T3 (da) 2023-11-06
AU2018260314B2 (en) 2021-12-09
CN110621678A (zh) 2019-12-27
MA44020B1 (fr) 2019-08-30
MD3395821T2 (ro) 2019-10-31
PT3395821T (pt) 2019-08-27
PL3615544T3 (pl) 2023-07-17
KR102492283B1 (ko) 2023-01-27
IL270153B2 (en) 2023-10-01
CY1121885T1 (el) 2020-10-14
ECSP19083967A (es) 2019-12-27
US11332480B2 (en) 2022-05-17
CN114736219A (zh) 2022-07-12
CN110621678B (zh) 2024-09-20
AU2022200250C1 (en) 2022-06-23
IL289963A (en) 2022-03-01
TWI807411B (zh) 2023-07-01
EP3395820A1 (en) 2018-10-31
CL2019003057A1 (es) 2020-02-21
PT3395820T (pt) 2019-08-07
CA3061518A1 (en) 2018-11-01
EP4101855B1 (en) 2023-08-02
DK3395820T3 (da) 2019-08-12
MA44021A (fr) 2019-05-15
ES2740073T3 (es) 2020-02-05
LT3395821T (lt) 2019-08-12
IL295044A (en) 2022-09-01
EP4047002A1 (en) 2022-08-24
EP3615544B9 (en) 2024-01-03
HRP20191443T1 (hr) 2019-11-15
DK3395821T3 (da) 2019-08-19
RS59174B1 (sr) 2019-10-31
KR20220109495A (ko) 2022-08-04
HRP20231233T1 (hr) 2024-01-19
TN2019000211A1 (en) 2021-01-07
SI4047002T1 (sl) 2023-07-31
US20240166666A1 (en) 2024-05-23
MX2019012812A (es) 2020-01-14
HUE046109T2 (hu) 2020-02-28
HUE062157T2 (hu) 2023-10-28
JP2018188431A (ja) 2018-11-29
US20180312529A1 (en) 2018-11-01
MA44020A (fr) 2018-10-31
HUE063736T2 (hu) 2024-01-28
JP2018188432A (ja) 2018-11-29
LT4047002T (lt) 2023-05-10
ME03467B (me) 2020-01-20
TN2019000210A1 (en) 2021-01-07
MX2021016058A (es) 2022-02-03
IL270153A (sl) 2019-12-31
ES2741901T3 (es) 2020-02-12
JP2020517709A (ja) 2020-06-18
RS59173B1 (sr) 2019-10-31
EP3615544A1 (en) 2020-03-04
IL289963B2 (en) 2023-10-01
HRP20230455T1 (hr) 2023-07-21
IL270153B1 (en) 2023-06-01
FI4101855T3 (fi) 2023-09-22
ZA201907119B (en) 2021-07-28
HUE045641T2 (hu) 2020-01-28
CN114751920B (zh) 2024-06-07
MD4101855T2 (ro) 2023-12-31
US11339180B2 (en) 2022-05-24
EP3395820B1 (en) 2019-05-15
LT4101855T (lt) 2023-08-25
CN114736219B (zh) 2024-06-07
BR112019022282A2 (pt) 2020-05-19
AU2022200249B1 (en) 2022-02-10
PH12019550224A1 (en) 2020-10-12
PL3395821T3 (pl) 2019-10-31
EP4101855A1 (en) 2022-12-14
HUE062032T2 (hu) 2023-09-28
HK1255941B (zh) 2020-04-29
ME03466B (me) 2020-01-20
PL3395820T3 (pl) 2019-11-29
PL4101855T3 (pl) 2023-12-27
ES2944344T3 (es) 2023-06-20
RS64174B1 (sr) 2023-05-31
SG11201909841RA (en) 2019-11-28
EP4047002B1 (en) 2023-03-08
US11713325B2 (en) 2023-08-01
AU2018260314A1 (en) 2019-10-31
KR102491180B1 (ko) 2023-01-20
FI3615544T3 (fi) 2023-05-23
IL295044B2 (en) 2023-11-01
AU2018260314C1 (en) 2022-04-21
MD4047002T2 (ro) 2023-08-31
CO2019011967A2 (es) 2020-02-18
RS64686B1 (sr) 2023-11-30
IL295044B1 (en) 2023-07-01
EP3615544B1 (en) 2023-03-22
AU2022200250B1 (en) 2022-02-10
JP6501946B2 (ja) 2019-04-17
JP7186723B2 (ja) 2022-12-09
US20210246146A1 (en) 2021-08-12
JOP20190254A1 (ar) 2019-10-27
HK1255938B (zh) 2020-04-29
JP7422812B2 (ja) 2024-01-26
JP6501947B2 (ja) 2019-04-17
KR102510975B1 (ko) 2023-03-16
WO2018197663A1 (en) 2018-11-01
LT3615544T (lt) 2023-05-10
JP7490835B2 (ja) 2024-05-27
FI4047002T3 (fi) 2023-05-22
SI4101855T1 (sl) 2024-03-29
HRP20191442T1 (hr) 2019-11-15
CN117865987A (zh) 2024-04-12
MD3615544T2 (ro) 2023-08-31
MA44021B1 (fr) 2019-08-30

Similar Documents

Publication Publication Date Title
GB201700814D0 (en) Compounds
IL288822A (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
IL289963A (en) Antitumor compounds
GB201704325D0 (en) Compounds
IL292489B2 (en) Morpholinylpyridone compounds
GB201703282D0 (en) Compounds
PT3615544T (pt) Compostos antitumorais
GB201721845D0 (en) Compounds
GB201721756D0 (en) Compounds
GB201721331D0 (en) Compounds
GB201709642D0 (en) Compounds
GB201706309D0 (en) Compounds
GB201706304D0 (en) Compounds
GB201703283D0 (en) Compounds